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THE UTILITY OF FECAL LACTOFERRIN MEASUREMENTS IN 
PREDICTING DISEASE ACTIVITY OF HOSPITALIZED PATIENTS WITH 
ULCERATIVE COLITIS 
 
KELLEN F. MANDEHR 
ABSTRACT 
 
Background: Early identification of pediatric patients with Inflammatory Bowel Disease 
(IBD), including ulcerative colitis and Crohn disease, is important to help clinicians 
design optimal treatment regimens.  Existing endoscopic techniques are effective in 
identifying disease activity.  However, these methods are invasive, expensive, and less 
amenable to serial measurement.  Recent studies have identified potential serologic and 
fecal biomarkers that may have the potential to provide clinicians with a more objective 
evaluation of disease activity.  In the case of ulcerative colitis (UC), in which disease is 
confined to the large intestine, the information provided by fecal biomarkers is likely to 
be more specific than that provided by serologic biomarkers.  Fecal lactoferrin (FLA) is 
one such biomarker that has shown to be useful not only in identifying levels of colonic 
inflammation, but also for use as a predictor of disease relapse and treatment efficacy.  
Measurement of fecal lactoferrin, in conjunction with information provided by other 
diagnostic modalities could expedite patient assessment and treatment.  Additionally, it 
has been suggested that fecal lactoferrin levels may also provide prognostic information 
about response to treatment and disease outcome in pediatric patients with UC. The goal 
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of this study is to explore the relationship between changes in FLA levels and response to 
medical therapy in hospitalized pediatric patients with UC.  
 
Methods: Serial stool samples were collected daily from 10 patients admitted for 
management of severe active UC. Of these 10 patients, 3 responded favorably to standard 
treatment with intravenous corticosteroid therapy and were discharged to complete a 
course of oral steroids. 7 were unresponsive to steroid therapy and went on to require 
rescue (more intensive) medical therapy.  Changes in FLA were correlated with steroid 
response and medical disposition at the time of discharge.  
 
Results: A t-test was performed to determine the significance of the differences in percent 
change in FLA levels between patients discharged on steroids and patients discharged on 
rescue therapy.  Patients discharged on steroids demonstrated a net decrease in FLA 
levels over the course of the first three days of steroid treatment while patients ultimately 
requiring rescue medical therapy demonstrated a net increase in FLA levels (mean values 
= -64.4% and +203.8%, respectively). A difference was found between the averages; 
however, this value did not reach statistical significance when analyzed with a t-test (p = 
0.18). 
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Conclusions: This study suggests that quantitative FLA levels may prove useful in 
predicting clinical course and discharge outcome in pediatric patients with ulcerative 
colitis.  Future research in this field should seek larger sample sizes, increased 
longitudinal sample collection, and the potential for a composite assessment that will 
yield additional objective measures of disease activity. 
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INTRODUCTION 
 
Inflammatory Bowel Disease (IBD) refers to a collection of idiopathic chronic 
inflammatory conditions affecting the gastrointestinal tract.  IBD arises most often during 
late childhood and early adulthood, demonstrating a peak incidence between the ages of 
15 and 30 years.  Approximately 25% of patients are diagnosed during childhood 
(Benchimol, et al. 2011).  Two major subtypes of IBD exist, including Crohn disease 
(CD) and ulcerative colitis (UC) (Medline, 2012).  The pathophysiology of both disorders 
is characterized by chronic inflammation as the cardinal feature. However, they can be 
distinguished based on clinical features, disease distribution, and endoscopic/histologic 
appearance.  More specifically, UC is limited to the mucosal layer of the large intestine.  
In contrast, inflammation in patients with CD often penetrates to involve the submucosa 
or serosa of the bowel wall and can affect virtually any part of the gastrointestinal tract, 
from the mouth to the anus (Higuchi & Bousvaros, 2013).  The pathogenesis of neither 
disorder has been fully elucidated.  However, data from recent studies suggests that the 
inflammatory response observed in patients with UC and CD may result from a 
combination of genetic vulnerability in the context of an inappropriate activation of the 
intestinal immune response against bacteria native to the gut (Saeed & Kugathasan, 
2008).  A second hypothesis regarding the development of IBD relates to what is now 
referred to as the “Hygiene Hypothesis”.  In this current “hyper-hygienic” age, children 
are now born and raised in the context of decreased and/or restricted microbial 
challenges.  As a result, our highly evolved, yet now underused, immune system is more 
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likely to respond aberrantly to native (self) antigens.  This may explain the recent 
increased incidence in autoimmune diseases including IBD, asthma, food allergies, and 
arthritis (Saeed and Kugathasan, 2008).  While many hypotheses exist regarding IBD 
causation, many more questions regarding its pathogenesis remain unanswered, making 
evaluation and treatment of these patients difficult.   
 
Clinical Features of the IBD 
Patients with UC and CD can present with similar clinical pictures. As such, 
clinicians typically rely on differences in the anatomic location or the nature of the 
mucosal inflammation to characterize a patient’s clinical signs and symptoms as being 
most consistent with either UC or CD.  UC is characterized by diffuse inflammation, 
beginning in the rectum and extending up in a confluent fashion to include part or all of 
the large intestine.  In contrast, inflammation in patients with CD is more often seen as 
discontinuous, and manifests “skip lesions” (Abraham & Cho, 2009; Hendrickson, et al. 
2002). Macroscopically, the inflammation in UC is typically restricted to the superficial 
mucosa, while the inflammation in patients with CD can be penetrating (i.e. extending 
through the mucosa to include the submucosa and serosa of the intestine) (Higuchi & 
Bousvaros, 2013).  Chronic and penetrating inflammation of this type can result in 
stricturing (i.e. narrowing of the intestine), perforation, or the development of fistulas (a 
pathologic connection of one portion of the intestine to another) (Hendrickson et al., 
2002).  The macroscopic features used to help differentiate patients with UC from those 
with CD are presented in Table 1 (Glickman, 2005). 
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The most common presenting clinical symptoms in patients with IBD include 
abdominal pain, diarrhea, and decreased appetite, (Mamula et al., 2003).  One dimension 
that can be used to help distinguish between UC and CD is the gross appearance of the 
patient’s stool.  The presence of blood and mucus in the stool is more likely to point to a 
diagnosis of UC (Bousvaros et al., 2007). UC patients might also present with acute 
systemic symptoms including tachycardia, fever, or dehydration.  In contrast, the 
penetrating nature of the inflammation in patients with CD can result in patients 
presenting with perianal abscesses (Higuchi & Bousvaros, 2013) or intestinal stricturing.  
Small bowel inflammation can also result in intestinal dysfunction and decreased nutrient 
absorption. Over the long-term, this malabsorption can result in patients with CD 
presenting with more indolent systemic signs and symptoms including poor weight gain, 
decreased linear growth, and delayed pubertal development (Mamula et al., 2003).  As 
such, the effects of IBD can have a greater impact on younger children, who are 
especially vulnerable to any alterations in growth patterns (Kelsen & Baldassano, 2008).   
 
Table 1: Pathological Features Useful in Distinguishing Ulcerative Colitis and 
Crohn Disease. This table displays some of the common clinical findings physicians use 
in differentiating patients with UC from those with CD. Taken and adapted from 
Glickman, 2005. 
 
Feature Ulcerative Colitis Crohn Disease 
Inflammation Continuous Discontinuous 
Rectal involvement Always Sometimes 
Ileal involvement Not typical  Frequent 
Upper gastrointestinal tract 
involvement 
Sometimes Frequent 
Fissures Absent Present 
Transmural involvement Absent Frequent 
Tissue granulomas Absent Present 
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Epidemiology of Inflammatory Bowel Disease 
 IBD has historically been most prevalent in Western societies including the US, 
UK, and Scandinavia.  However recent epidemiologic studies have demonstrated an 
increased prevalence on a global scale.  To this end, patients with IBD are now more 
frequently identified in Asia, Latin America, Africa, and part of Southern Europe (Loftus, 
2004; Griffiths, 2004; Benchimol et al., 2011).  The increasing incidence of IBD in less 
developed countries is believed to be caused by cultural “Westernization”, including 
fundamental changes in dietary and other lifestyle habits (Loftus, 2004).  Other 
demographic factors relevant to IBD include gender.  Women appear to have a higher 
incidence of CD than men, while the opposite has been reported in patients with UC 
(Benchimol et al., 2011).  With respect to racial and ethnic factors, there has been a 
significant increase in IBD diagnoses among African-American patients.  In contrast, 
Asian, Latino, and Native American populations continue to demonstrate inexplicably 
lower incidence rates (Loftus, 2004).  There appears to be a significant age or 
developmental component to the pathogenesis of IBD as well.  While the ratio of CD to 
UC patients in adult populations is close to 1:1, the ratio in children is much closer to 3:1 
(Sauer & Kugathasan, 2009).  
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Etiology of Inflammatory Bowel Disease 
 The pathogenesis of IBD appears to be the end result of a combination of genetic 
and environmental factors.  Currently, twin studies provide the most readily interpretable 
genetic evidence as stated by Benchimol et al., 2011: 
Twin studies have shown that inherited genetic risk factors alone play a small role in the 
pathogenesis of IBD (16%-36% concordance rates in monozygotic twins and 4% 
concordance rates in dizygotic twins). 
The concordance rate appears to be higher in patients with CD than in those with UC.  
Overall, the risk of developing IBD is believed to be up to 14-15 times greater in first-
degree relatives (Binder, 1998).   
 Environmental risk factors are also relevant in the pathogenesis of IBD (Saeed & 
Kugathasan, 2008).  Some of the most significant and best-studied environmental factors 
associated with the development of IBD include smoking, appendectomy, diet, and 
environmental disturbances of the internal microbiome (Saeed & Kugathasan, 2008; 
Loftus, 2004; Ng et al., 2013).   Interestingly, the effect of smoking on the clinical course 
of IBD appears disease-specific.  Smoking has been shown to have an inverse 
relationship with the development of UC, while smoking appears to increase disease 
severity in patients with CD.  Likewise, appendectomy is seen as a protective measure 
from developing UC, while some studies have shown a correlation between 
appendectomy and increased CD (Loftus, 2004).   
 The role of the internal intestinal flora in the development of IBD is yet to be fully 
elucidated, but the issues are outlined by Ng et al. (2013) and Frank et al. (2007) in their 
papers: 
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The dysbiosis reported in IBD is likely to be a consequence of changes in environment 
including hygiene and food, resulting in imbalance in the microbial-host relationship with 
mucosal barrier dysfunction and reduced microbial diversity. 
Indeed, diet is seen as an important modifier of an individual’s gut flora.  In keeping with 
the “hygiene hypothesis”, it is thought that children born in "westernized" areas of low 
microbial exposure are more prone to developing IBD than those in high-exposure 
regions because appropriate tolerance is not established early in life (Saeed & 
Kugathasan, 2008).  Two other dietary concepts are equally noteworthy.  First, the advent 
of refrigeration (referred to as the “cold-chain hypothesis”) has led to the prolonged life 
span of food and consequently, the bacteria that colonizes it (Loftus, 2004).  Second, the 
revolution in antibiotic development and widespread use may be leading to increased 
incidence of IBD through alterations in gut flora (Ng et al., 2013).  As changes in diet, 
antibiotic exposure, and food preparation/storage have all mirrored the increase in IBD, 
additional studies are going to be necessary to discern the complex interplay between 
genetic and environmental factors (Mamula et al., 2003). 
 
Pathogenesis of Inflammatory Bowel Disease 
 Mucosa-associated lymphoid tissue (MALT) comprises a significant portion of 
the human immune system and resides in mucosal surfaces lining the body.  More 
specifically, this includes the gut-associated lymphoid tissue (GALT), which is found in 
the intestinal mucosa and is responsible for protecting the body from infective and atopic 
enteric challenges (Medscape, 2012).  GALT is the largest collection of lymphoid tissues 
in the body and consists of both organized lymphoid tissues, including mesenteric lymph 
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nodes and Peyer’s patches, as well as IgA-producing lymphocytes that are distributed 
throughout the intestinal lamina propria (Forchielli & Walker, 2005).  Dendritic cells, 
which are highly specialized antigen-presenting cells, also reside within the intestinal 
mucosa and participate in immune surveillance and help to orchestrate immune responses 
by activating specific T-lymphocyte populations (Tezuka & Ohteki, 2010).   
The sequence of immune events in mediating or propagating the inflammation 
observed in patients with IBD is not certain. However, it is clear that an interaction 
between the GALT, the intestinal epithelium, and the commensal intestinal flora is 
crucial (Abraham & Cho, 2009). Poorly regulated mucosal immune responses, likely 
resulting from aberrant bacterial signaling from the intestinal lumen, are a potential risk 
factor for ongoing bowel inflammation (Forchielli & Walker, 2005).  Commensal 
bacteria can act to limit proinflammatory signaling pathways that are mediated by cell-
surface Toll-like receptors (TLR) and cytosolic NFkB proteins. Without these 
interactions, immune tolerance of gut flora cannot develop appropriately, and this can 
help to drive intestinal inflammation (Tezuka & Ohteki, 2010).  In patients with IBD, this 
inflammation is chronic and leads to progressive epithelial injury and ulcerations 
(Abraham & Cho, 2009).   
 
Diagnostic Techniques and the Importance of Disease Differentiation 
Patients with CD and UC can present with many of the same clinical features.  
However, differences in the pathogenesis, as well as the nature of the inflammatory 
responses observed in these disorders, can lead to differing complications and prognoses 
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(Kelsen & Baldassano, 2008).    As such, the frequently indolent nature of the 
inflammation observed in patients with CD leaves them more vulnerable (60-88% of 
patients) to growth failure and delays in sexual maturation than in patients with UC (6-
12% of patients) (Hendrickson et al., 2002).  Therefore, there is a clear premium on 
identifying disease at an early age or early in the disease course to prevent these 
potentially irreversible clinical complications (Sauer & Kugathasan, 2009).   
Endoscopic study with mucosal biopsy and radiological study are accepted as the 
standard of care in evaluating children with suspected IBD.  Endoscopy with biopsy can 
be definitive in differentiating patients with CD from those with UC, given differences in 
the endoscopic and histologic appearance of involved mucosa (Hendrickson et al., 2002; 
Bousvaros et al., 2007; Higuchi & Bousvaros, 2013).  Radiologic studies permit an 
assessment of small bowel loops that are typically inaccessible using standard 
endoscopic/colonoscopic techniques (Hendrickson et al., 2002).  While these studies are 
considered the “gold standard” in diagnostic testing, their sensitivity and specificity 
parameters fall short of 100% (Sherwood, 2012).  As a result, studies are underway to 
define more expedient and accurate ways of diagnosing and differentiating patients with 
IBD (Bousvaros et al., 2007). 
 
Treatment options  
The range of options available to clinicians to treat their patients with IBD has 
greatly increased.  Nonetheless, there is little in the way of evidence-based data to 
formulate a unified/standard clinical approach to the management of patients with either 
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CD or UC (Sauer & Kugathasan, 2009).  Medications used to treat patients with IBD 
generally fall into three categories: those used to induce disease remission, those used to 
maintain disease remission, and those used in patients with refractory disease (so called 
“rescue therapy”).  Surgery is typically reserved for those patients that have failed 
medical therapy or developed a complication, including perforation, obstruction, and 
growth delay (Sauer & Kugathasan, 2009).  Induction agents are more potent and 
typically used short term due to the potential for detrimental long-term side effects.  
Corticosteroids (administered either orally or intravenously) are the most widely used 
class of medications for inducing remission in patients with either UC or CD. 5-
aminosalicylates (ASAs) have shown to be effective in inducing remission in patients 
with mild-moderate UC (Higuchi & Bousvaros, 2013).   Clinicians often use 
immunomodulators, including 6-mercaptopurine (6MP) or Azathioprine (AZA), to 
maintain CD and UC disease remission. In instances in which patients fail to respond to 
steroid and/or immunomodulation therapy, clinicians may choose to employ rescue 
therapy with more potent immunosuppressive drugs like tacrolimus (Sauer & 
Kugathasan, 2009; Higuchi & Bousvaros, 2013).  The recent advent of biologic 
immunomodulation using antibodies to TNF-α has been proven effective for treating 
patients with CD and UC (Abraham & Cho, 2009).  In the event of complete medical 
treatment failure, surgery is typically advised.  In patients with UC, total colectomy is 
recommended.  In contrast, patients with refractory CD are typically treated with isolated 
small or large bowel segmental resection (Higuchi & Bousvaros, 2013).  
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Treatment Course 
 The course of treatment for pediatric patients presenting with moderate to severe 
UC can vary from center to center (Sauer & Kugathasan, 2009).  Within the scope of this 
variability, IBD Centers including Boston Children’s Hospital follow a commonly used 
treatment plan for patients that exhibit disease flares.  Typically, children admitted with 
moderate to severe colitis will initially be treated with intravenous corticosteroids, 
possibly with adjunct therapy (antibiotics).  Patients responding to this course of therapy 
(approximately 80%) will be discharged to complete a course of oral steroid therapy and 
a maintenance medication (ASA, immunomudulator, or biologic).  If it becomes apparent 
after 5-10 days that the patient is not responding to steroid therapy, it becomes necessary 
to discuss more aggressive treatment, including the use of more potent (rescue) 
immunosuppressive therapies or surgery (colectomy) (Higuchi & Bousvaros, 2013).  
Rescue medications currently include tacrolimus, infliximab, and cyclosporine.  Previous 
data suggest that 80% of patients failing to respond to corticosteroid therapy will 
ultimately respond to rescue therapy.  Those failing rescue therapy are typically referred 
for surgery.  Patients responding to rescue therapy are transitioned to maintenance agents 
including immunomodulators or infliximab for maintenance (Higuchi & Bousvaros, 
2013; (Sauer & Kugathasan, 2009).  As such, there is a pressing need to develop newer 
generations of biomarkers and treatment algorithms to assist clinicians in discerning 
which patients are likely to respond to steroid therapy and which are likely to go on to 
rescue or surgery.  Earlier identification of these refractory patients will shorten 
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hospitalization; decrease morbidity related to central venous access and parenteral 
nutrition; and lower overall healthcare costs. 
 
Serological and Fecal Biomarkers 
 There are many diagnostic modalities currently available for use in evaluating 
patients with suspected IBD.  However, many of these technologies are limited by cost, 
inconvenience, or patient morbidity.  Hence, clinicians continue to seek novel methods 
that are less invasive, more specific, and less costly for use in the diagnosis of patients 
with IBD (Kane, Sandborn, Rufo et al., 2003; Assche, 2011).  To that end, efforts are 
currently underway to develop and validate specific serologic or fecal biomarkers that 
can be used to reduce dependence on more costly and invasive studies, assess disease 
activity and disease severity more directly, and assist clinicians in predicting the 
likelihood for disease relapse in individual patients (Masoodi et al., 2011).  Biomarkers 
may also provide more valid objective data when used in conjunction with existing 
subjective clinical disease activity indices (Assche, 2011).   
 The most well known serological markers that have been employed by clinicians 
to assess disease activity in patients with IBD include C - reactive protein (CRP) and 
Erythrocyte Sedimentation Rate (ESR) (Masoodi et al., 2011).  However, both measures 
lack disease specificity and can be influenced by infection or inflammation in any part of 
the body.  As such, fluctuations in these values are less useful in IBD patients with 
concomitant illnesses (Assche, 2011; Abraham & Kane, 2012; Sherwood, 2012). 
Nonetheless, until more specific biomarkers for IBD have been identified and validated, 
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clinicians will continue to rely on ESR and CRP to help assess for active inflammation in 
patients with UC and CD (Assche, 2011; Sherwood, 2012). 
 Another serological marker that has been in widespread use for assessing patients 
with suspected IBD is Anti-Saccharomyces cerevesiae antibody (ASCA). Existing data 
suggest that this serologic antibody to a commensal yeast may be a useful tool in 
identifying patients with IBD and distinguishing patients with CD from those with UC.  
While ASCA has demonstrated higher specificity and sensitivity than other serological 
antibodies, data from this assay is not sufficiently reliable to be used for diagnostic 
purposes and subsequent endoscopic studies are still mandated.  As such, efforts are 
underway to define the clinical contexts in which serologic ASCA measurements may 
prove most useful (Reese et al., 2006; Prideaux, et al., 2011, Gisbert et al., 2009). 
 The application of fecal biomarkers (lactoferrin and calprotectin) for use in the 
diagnosis and interval assessment of patients with IBD is becoming increasingly 
widespread.  This technology has the advantages of being generally inexpensive, non-
invasive, and amenable to serial measurement in the same patient over time (Masoodi et 
al., 2011).  Unlike serum biomarkers, fecal biomarkers are a product of the mucosal 
immune system of the GI tract, and are therefore much more sensitive and specific than 
their serologic counterparts in assessing inflammation of the intestinal mucosa in patients 
with IBD (Assche, 2011; Masoodi et al., 2011). Additionally, fecal biomarkers are likely 
to be more accurate than serological testing in differentiating patients with an 
inflammatory process (IBD) from those with non-inflammatory GI conditions like 
Irritable Bowel Syndrome (IBS) (Abraham & Kane, 2012; Masoodi et al., 2011).  
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However, while elevated fecal lactoferrin and calprotectin levels are sensitive to mucosal 
inflammation, they are generally unable to discern if the intestinal inflammation being 
evaluated is the result of an autoimmune (e.g. IBD) or an acute infectious (e.g. 
Salmonella, Shigella, Yersinia, Campylobacter, and/or E. coli) process.  Additionally, 
existing fecal biomarkers do not differentiate between CD and UC (Abraham & Kane, 
2012).   
 
Fecal Calprotectin  
 One biomarker in widespread use for evaluation of intestinal inflammation is 
fecal calprotectin (FC), a calcium-binding protein with antibacterial, antifungal, and 
metalloproteinase-inhibitory properties (Masoodi et al., 2011; Beniwal & Harrell, 2010). 
FC is derived from neutrophil granules, so the degree of inflammation present in the 
intestine is believed to correlate directly with the levels of FC (Abraham & Kane, 2012; 
Masoodi et al., 2011; Sherwood, 2012). Recent findings further indicate that FC 
correlates with endoscopic disease activity better than preexisting activity indices and 
serum biomarkers (Schoepfer et al, 2013).    While FC is viewed as a reliable indicator of 
inflammation, a number of factors must be considered in interpreting any results.  
Specifically, FC levels may be affected by NSAID use and blood loss exceeding 100mL 
of total blood volume (Masoodi et al., 2011; Abraham & Kane, 2012).  Due to these 
potential confounding variables, clinicians are looking towards other fecal biomarkers to 
reflect not only disease activity but also provide better indication of treatment response or 
the need for escalating clinical intervention. 
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Fecal Lactoferrin 
 Fecal Lactoferrin (FLA) is a well-established fecal biomarker of inflammation.  
FLA is a small iron-binding glycoprotein that, like calprotectin, is also found in 
neutrophil granules and body fluids including breast milk, tears, and saliva.  FLA 
displays bactericidal properties in-vitro and in-vivo and has evolved to play an intrinsic 
role in innate immunity (Kane et al., 2003; Gisbert et al., 2009).  Previous data has 
demonstrated that changes in the level of this fecal biomarker can be useful in assessing 
the degree of inflammation in patients with IBD (Masoodi et al., 2011; Walker et al., 
2007).  To that end, FLA levels are significantly higher in patients with IBD than those 
with Irritable Bowel Syndrome (Basso et al., 2013, Abraham & Kane, 2012; Beniwal & 
Harrell, 2010).  Ongoing studies should assist in discerning whether FLA might also be 
useful in monitoring disease activity, assessing therapeutic efficacy, and predicting 
disease relapse in patients with IBD. 
Ultimately, the benefits of using a biomarker such as FLA – which is cheap and 
readily assessed (ELISA), stable at room temperature, and more specific than serologic 
inflammatory markers (CRP and ESR) – are quite promising (Gisbert et al., 2009).  FLA, 
like FC, may provide complementary information to that derived using existing clinical 
disease activity indices, including the Pediatric Ulcerative Colitis Activity Index 
(PUCAI), in which disease activity is weighted based on a particular patient’s subjective 
impressions (Assche, 2011).  While the utility of FLA has yet to be fully explored, a 
better understanding of this marker could further our understanding of IBD and promote 
the development of newer generations of non-invasive biomarkers for use in the 
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diagnosis and assessment of patients with IBD (Gisbert et al., 2009; Kane et al. 2003).  
While research has been done to evaluate the predictive value of fecal biomarkers on 
treatment response, need for surgery, and disease relapse, more testing will be required 
before FLA and fecal calprotectin can be used reliably in clinical practice (Abraham & 
Kane, 2012). Ultimately, the clinical validation of fecal biomarkers, used in conjunction 
with information provided by disease activity indices and past medical history, would 
enable physicians to more expediently assess patients with symptoms suspicious for IBD 
(Gisbert et al., 2007, Abraham & Kane, 2012).  The use of fecal biomarkers may also 
facilitate and improve ongoing monitoring of disease activity and response to therapy in 
patients with UC and CD (Assche, 2011). 
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SPECIFIC AIMS 
 
 Current and past studies demonstrate that numerous inflammatory biomarkers 
exist for identifying a patient with IBD.  More specifically, research into specific fecal 
biomarkers indicates that FLA appears to be a highly sensitive and highly specific marker 
of intestinal inflammation. Moreover, FLA has shown to be very useful in discriminating 
patients with IBD from those with IBS or healthy controls (Kane et al., 2003; Walker et 
al., 2007).  Given the notion that FLA appears to be a useful marker for intestinal 
inflammation, we hypothesize that FLA levels are a useful determinant of disease activity 
in patients with IBD, specifically UC.  Therefore the goal of this study is to determine 
whether serial FLA measurements are predictive of both the response to steroid therapy 
and the likelihood of a clinical relapse.  These measurements will then be used in 
conjunction with PUCAI scores and endoscopic study results to identify the relationship 
between FLA levels and these more standardized tools of disease evaluation.  More 
specifically, we will evaluate: 
1. Whether the changes in quantitative FLA measurements predict the likelihood of 
response to either parenteral or oral steroid therapy 
2. The relationship between FLA levels and existing diagnostic and clinical 
assessment tools (e.g. PUCAI and/or clinical lab inflammatory markers) 
3. The feasibility of developing a composite predictive disease metric for IBD 
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The data collected in this study will further define the predictive utility of FLA levels as a 
noninvasive fecal biomarker for evaluation of disease activity, steroid therapy response, 
the likelihood of disease relapse, and the potential for either rescue therapy or surgical 
intervention in patients with UC.  
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METHODS 
 
Study Population 
 Consecutive pediatric patients (aged ≤ 21 years of age) with known or suspected 
diagnosis of UC were admitted to the Gastroenterology (GI) inpatient service at Boston 
Children’s Hospital for the management of their symptoms.  The definition of UC, 
including disease subtypes (ulcerative proctitis, distal UC, or pancolitis) was determined 
using standard clinical, endoscopic, histological, and radiological evidence of disease.  
Patients with Crohn Disease or undetermined intestinal malignancies were not recruited 
for the study. Additionally, patients who were diagnosed with HIV and/or Hepatitis B or 
C were excluded from the study.  Patients who refused to provide serial stool samples 
were also excluded from study participation.   
 
Recruitment Methods 
 Patients were recruited using access of Cerner® Powerchart, a patient medical 
record program, in conjunction with clinical interactions among GI inpatient service 
physicians.  Powerchart is one medical record program used by the Boston Children’s 
Hospital to securely track and store patient medical information.  Following identification 
of potential study candidates, patients were approached on the GI inpatient floor 
regarding study participation. Following explanation of the details of the study and the 
role of the subjects, both subjects and parents/guardians were given an opportunity to ask 
questions.  If parents and patients remained interested in participating, informed consent 
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and assent of the participant and parents/guardians were obtained, respectively.   Enrolled 
subjects were assigned a study designation number to maintain anonymity.   
 
Sample Collection and Processing 
 Patients were asked to provide serial stool samples during their stay in the 
hospital and were also given the option to provide further samples following discharge.  
Stool samples were collected daily, the first one typically within 12 hours of admission 
and the final one upon patient discharge from the hospital.  While daily samples were not 
used for study purposes, the procedure was implemented to facilitate sample collection 
for the nursing staff.  The samples that were collected by nursing staff were then stored in 
a 4° Celsius refrigerator. The most relevant samples for this study were collected on days 
1 (baseline), 3, 5, and discharge.  Collected samples were divided into three 2-mL 
aliquots, labeled with the appropriate information, and stored in a -80° Celsius freezer.  
Samples remained in this freezer until they were ready for batch shipment to our testing 
facility.  Shipment involved only one sample aliquot, leaving two in the freezer, in the 
event that samples were lost or needed to be retested at a later time point. 
 Patients agreeing to participate in the outpatient portion of the study were asked to 
provide stool samples every 14 days for an additional 12 weeks or until the end of the 
patient’s steroid therapy course.  Patients were provided with the proper materials to 
collect and store stool samples prior to mailing. For outpatient sample processing and 
storage, an identical procedure to that of inpatient samples was followed.   
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Sample Testing 
Batched stool samples were shipped to TechLab Inc. ® (Blacksburg, Virginia) 
who sponsored this study.   TechLab Inc. ® personnel were blinded to disease activity.  
Two FLA tests developed by TechLab Inc. ®, IBD-SCAN™ (quantitative) and IBD-
CHEK™ (qualitative), were performed on and results were determined for the fecal 
specimens following a 1:20 dilution in the kit.   IBD-SCAN™ quantifies FLA in 
micrograms/milliliter (µg/mL). A reading of greater than or equal to 7.25 µg/mL was 
defined as an elevated FLA level, while values less than 7.25 µg/mL were considered 
baseline (normal).  IBD-CHEK™ confirms the presence of FLA in terms of optical 
density (OD) at 450nm/620nm on a dual wavelength spectrophotometer.  A reading of 
greater than or equal to .160 was defined as a positive result for stool samples.   
(TechLab®, 2008).   
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Case Report Forms 
 Case Report Forms (CRF) were completed for each patient that was enrolled in 
the study and provided at least one stool sample.  CRFs were designed to expedite 
collection of relevant patient information from the electronic medical record and to 
facilitate data entry and analysis.   
 Inpatient CRFs include nine sections. Data in sections A-I are collected on the 
first day, while data for E-I are collected for every day that the patient is in the hospital.  
Sections A-D include general information, demographic information, patient disease 
information, and admission information, respectively. Figure 1, on the following page, 
provides a more detailed illustration of patient medical information (including diagnosis) 
necessary for the conduct of the study.   
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Figure 1: Disease Information and Admission Information in the Case Report Form. 
Sections C and D from the CRF include details of each patient’s disease classification, 
date of diagnosis (based on colonoscopy results), reason for hospital admission (along 
with the start date of symptoms), and any prior GI surgical treatments.  While most 
patients are admitted for disease flares, undiagnosed patients were also included in this 
study. 
 
SECTION C: DISEASE INFORMATION 
C1. Date of Diagnosis:                    __ __ /__ __ /__ __ __ __ 
C2. Montreal Classification 
 Disease Extent:  Ulcerative proctitis…………1 
     Distal UC………………………2 
     Pancolitis……………………..3 
 
C3: Colonoscopy Information 
C3a. Date of Colonoscopy at Diagnosis:  __ __ /__ __ /__ __ __ __ 
C3b. Date of Last Colonoscopy:  __ __ /__ __ /__ __ __ __ 
 
 
 
SECTION D: ADMISSION INFORMATION 
D1. Date of Admission:  __ __ /__ __ /__ __ __ __ 
 
D2. Reason for Admission:  
    Diagnosis……………………………………………………. 1 
    Disease Flare…………………………….………………..2 
D3. Date of Onset of Symptoms or Flare:  __ __ /__ __ /__ __ __ __ 
 
D4. Prior Surgical Treatment:         Yes………..1 
(If 0, skip to E1)            No………….0 
D4a. Date:  __ __ /__ __ /__ __ __ __ 
D4b. Type:  Ileocecal Resection………………………………   1 
   Stricturplasty………………………………………..  2 
   Right Hemicolectomy……………………………  3 
   Left Hemicolectomy……………………………..  4 
   Colectomy and ileoanal pull through…..  5 
Other (specify_______________)………  6 
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Among the data that were collected daily along with stool samples were PUCAI 
(Section E) scores, fecal lab levels, and patient blood lab values that corresponded to that 
day’s stool sample.  Figures 2 and 3, on the following pages, provide a detailed view of 
the sections that were used to evaluate a patient’s disease activity during his/her stay in 
the hospital. 
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Figure 2: Activity Index Scores, Specimen and Patient Lab Data in the Case Report 
Form – Section E records the PUCAI score as dictated by the patient. Section F includes 
results obtained from studies completed at TechLab, Inc. ®. Section G (also from 
hospital visit) provides patient’s clinical lab values from each hospital day.   
  
SECTION G: BLOOD WORK 
CBC  
G1. WBC _ _ . _ _  K cells/uL 
G2. Hb _ _. _ g/dL 
G3. HCT _ _ _ . _ mg/dL 
G4. PLT _ _ _ _ mg/dL 
G5. MCV _ _. _ fL 
G6. Neutrophils _ _ % 
G7. Lymphs _ _ % 
G8. Eos _ _ % 
G9. Monos _ _ % 
Chemistry  
G10.   Albumin _ . _ g/dL 
G11.   ESR _ _ mm/hr 
G12. Amylase _ _ _ unit/L 
G13. ALT _ _ unit/L 
G14. Bilirubin (Tot) _ . _ mg/dL 
G15. Alkaline Phosphatase _ _ _ unit/L 
G16. CRP _ . _ _mg/dL 
SECTION E: ACTIVITY INDEX SCORES 
E1. PUCAI Score:           _ _ 
E2. PUCAI Components 
E2a. Abdominal Pain………………………………………………………………..0    5    10 
E2b. Rectal Bleeding………………………………………………………………..0    10   20   30 
E2c. Stool consistency of most stools……………………………………..0    5    10 
E2d. Number of stools per 24 hours………………………………………..0    5    10    15 
E2e. Nocturnal Stools………………………………………………………………..0    10 
E2f. Activity Level………………………………………………………………………0    5    10 
E3. Disease Severity (circle 1):  Remission     Mild UC      Moderate UC     Severe UC 
 
SECTION F: FECAL LAB LEVELS                        Stool Collected?  Yes……1    No……0 
F1: Date Fecal Labs Complete at Techlab:                   __ __/__ __/__ __ __ __ 
F2: IBD- CHEK™ Fecal Lactoferrin (OD450/620):  _ . _ _ _ 
F3. IBD-SCAN™ Fecal Lactoferrin (µg/mL)    _ _ _ . _ 
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Figure 3: Patient Discharge Outcome in the Case Report Form – Section UU 
includes the patient’s discharge medications/interventions following his/her hospital visit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SECTION UU: Discharge Outcome (Yes
1
/No
0
) 
 
 
2a. Steroids 1 0 
2b. 
Immunomodulators 
(Specify:_______) 
1 0 
2c. Biologics  
(Specify:_______) 
1 0 
2d. ASA 
(Specify:_______) 
1 0 
2e. Antibiotics 
(Specify:_______) 
1 0 
2f. Tacrolimus 
(Specify:________) 
1 0 
2g. Surgical 
Intervention 
(Date of procedure: 
_______________; 
Type of 
Procedure:_______
_____________) 
1 0 
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Statistical Analysis 
 
 Data was collected and patient outcome was dichotomized into two populations: 
those that were medically responsive and subsequently discharged on corticosteroids and 
those that had medically refractory disease and required rescue (tacrolimus/infliximab) 
therapy.  These two populations were then compared with respect to FLA levels (IBD-
SCAN™). For both of the populations, the mean, standard deviation, median, and 
interquartile ranges were calculated. Appropriate parametric (t-test) and non-parametric 
(Wilcoxon rank-sum test) statistical testing was then used to determine statistical 
significance of the differences in percent change from day 1 to day 3 of hospitalization 
between the two groups of patients with respect to FLA levels (IBD-SCAN™).    
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RESULTS 
 
Patient Population 
 A total of 19 patients diagnosed with UC provided informed consent prior to 
participation in this study. As seen in Figure 4, 10 of the 19 patients provided samples 
from at least the first three days of their hospitalization while the remaining 9 did not 
have sufficient sample provision to allow for analysis.  Comparison of fecal and 
biochemical data collected on the day of admission and Day 3 of the hospital stay were 
then used for analysis.  
 
 
Figure 4: Number of Patients and Sample Provision. 19 total patients (red bar) were 
enrolled in this study following provision of at least one stool sample.  Of these 19, 10 
were analyzed based on samples provided from day of admission and day 3 of 
hospitalization (yellow bar).  9 were excluded from the analysis due to insufficient 
sample provision during their hospital courses (blue bar). 
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We evaluated FLA levels as a prognostic outcome measure (discharged on 
steroids vs. need for rescue therapy).  As seen in Figure 5, 3 patients were discharged on 
steroid therapy while 7 were discharged on rescue therapy (e.g. tacrolimus or infliximab).  
 
 
Figure 5: Discharge Outcome of Analyzed Patients. 10 patients provided stool samples 
from at least day of admission and day 3 of hospital stay (red bar) and were separated 
into one of two groups based on their discharge disposition. Of the 10 patients used, 3 
were discharged on steroids (yellow bar) while 7 were discharged on rescue medications 
such as tacrolimus or infliximab (blue bar). 
 
 
For the purpose of this study, predictive value of FLA was based on the IBD-
SCAN™ values, since this assay has been previously validated as a continuous measure. 
 
Fecal Lactoferrin (IBD-SCAN™) and Discharge Outcome 
 A t-test was performed to distinguish whether FLA levels (IBD-SCAN™) would 
prognose discharge disposition. Values including the mean, standard deviation, median, 
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and interquartile range for both patient groups (steroid therapy or rescue therapy) on both 
days is provided in Table 2.  Additionally, Figures 6 and 7 provide a graphical 
representation of the data for day of admission and day 3 of hospitalization, respectively.  
Patients that were discharged on steroids had median FLA levels on admission (653.3 
g/mL) that were almost 10-fold greater than values of patients put on rescue therapy 
(96.5 g/mL).  However, by day 3, median FLA levels for both patient populations were 
statistically indistinguishable (310.0 g/mL and 321.7 g/mL, respectively)  
 
Table 2: Distribution of FLA Levels for Two Patient Groups in g/mL. 10 patients 
had stool samples analyzed for FLA levels (IBD-SCAN™) and were segregated into one 
of two groups.  3 patients were categorized as discharged on steroids and 7 patients were 
categorized as discharged on rescue therapy.  The differences in values are displayed 
above, however, no statistical significance was found. *p = 0.51  
 
 Day of Admission Day 3 
 N 
Mean 
(SD) 
Median 
(IQR) 
 
N 
Mean 
 SD) 
 
Median 
(IQR) 
Discharged on 
steroids 
3 
662.3 
(605.0) 
653.3 
(61.8,127.17) 
3 
263.1 
 229.1) 
310.0 
(14.2, 
465.0) 
Rescued with 
Tacrolimus/infliximab 
7 
307.5 
(391.1) 
96.5 
(81.7,543.3) 
7 
303.5 
 253.8) 
321.7 
(75.4, 
503.3) 
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Figure 6: Day of Admission Distribution of FLA Levels for Two Patient Groups. 
This chart is a graphical representation of the values listed previously in Table 2 for day 
of admission. IBD-SCAN™ values are listed on the y-axis (g/mL). The ranges of these 
values in the two populations appear similar.  However, differences between the median 
and IQR values for the two populations were not found to be statistically significant (p = 
0.51) 
 
FLA  
Level  
[g/mL] 
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Figure 7: Day Three Distribution of FLA Levels for Two Patient Groups. This chart 
is a graphical representation of the values listed previously in Table 2 for day 3 of 
hospitalization.  IBD-SCAN™ values are listed on the y-axis (g/mL). As seen in the 
diagram, the range of values between the two groups is quite different. However, the 
median and IQR values for the two populations are found to be similar. Once again, the 
differences were not found to be statistically significant (p = 0.51) 
 
  
 
 
 
 
FLA  
Level  
[g/mL] 
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 Using the above data, the percent change in FLA levels for both populations was 
calculated in order to determine whether trends could be found. Figure 8 provides a 
visual representation of the trend for each patient during their respective hospital stay.   
 
 
Figure 8: Trend in FLA Levels for Two Patient Groups. This chart is a graphical 
representation of the changes in FLA levels for each of the 10 patients analyzed for the 
study from day of admission to day 3 of hospitalization.  Patients discharged on steroids 
demonstrated an overall decline in levels from day 1 to day 3 (red lines).  Patients 
discharged on rescue therapy demonstrated a range of outcomes for their hospital stays 
(yellow lines).  IBD-SCAN™ values are listed on the y-axis (g/mL). 
 
These changes were used to calculate the total percent change for each patient.  
Results are shown in Table 3 and described graphically in Figure 9. The data revealed 
that patients that were medically responsive experienced a drop (-64.4%) in FLA over the 
first three days of their admission, while those that ultimately required rescue therapy 
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experienced an increase (+203.8%) in FLA. The changes in mean FLA levels approached 
but did not reach statistical significance (*p = 0.18). 
 
Table 3: Percent Change in FLA Levels of Two Patient Groups. This table 
illustrates the differences in percent change between the two patient populations.  Patients 
discharged on steroids demonstrated a negative percent change.  Patients discharged on 
rescue therapy demonstrated an overall increase in percent change. (*p = 0.18) 
 
 
Percent change between admission and Day 3 
N Mean  SD) Median (IQR) 
3 
-64.4 
(12.3) 
-63.4 
(-77.1, -52.6) 
7 203.8 (304.1) 
123.7 
(-62.5, 428.8) 
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Figure 9: Percent Change in FLA Levels of Two Patient Groups. This chart is a 
graphical representation of total percent changes (day of admission to day 3) in FLA 
levels for both patient populations analyzed. Patients discharged on steroids demonstrated 
an overall percent change of -64.4% (blue bar).  Patients discharged on rescue therapy 
demonstrated an overall percent change of +203.8% (yellow bar).   
 
 
A generalized linear model and two-sample t-test were used in order to predict the 
change in FLA levels between day of admission and day 3.  Since only two variables 
were assessed, the tests yielded the same results.    There was a difference between the 
percent changes in FLA levels for the two populations.  Yet, the effect of change in FLA 
levels did not quite reach statistical significance (p = 0.18). 
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DISCUSSION 
  
Inflammatory Bowel Disease (IBD) occurs in children and adults throughout the 
world.  While the causes of the disease are not yet identified, much effort has been 
applied to disease etiology, both from a genetic and environmental standpoint 
(Benchimol et al., 2011; Binder, 1998; Saeed & Kugathasan, 2008). Similarly, ongoing 
studies are centered on efforts to develop less invasive and more reliable ways to identify 
and manage patients with these disorders. To this end, the development of improved fecal 
biomarkers may contribute to a model of care that is less invasive, more cost effective, 
and more time efficient (Kane, Sandborn, Rufo et al., 2003; Assche, 2011).  
While it is widely accepted that biomarkers such as Fecal Lactoferrin (FLA) and 
Fecal Calprotectin (FC) are useful in discriminating between both affected and unaffected 
patients (Abraham & Kane, 2012; Masoodi et al., 2011), as well as active and inactive 
disease states, there is a premium on incorporating these measure in diagnostic and  
prognostic algorithms. At this stage, neither differentiation of disease type (i.e. CD versus 
UC) nor the ultimate disease outcome can be reliably evaluated using fecal biomarkers 
(Abraham & Kane, 2012).  Relatively little research has been conducted in order to 
determine the predictive utility of FLA levels in regards to treatment outcome, 
specifically while patients are hospitalized.  The ability to use fecal biomarkers to quickly 
gather information about which treatment methods a patient will require while in the 
hospital has important implications.  Among the most notable, patient care can be 
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implemented much more rapidly and therapy upon discharge will be more easily 
elucidated.  This project hopes to begin to uncover relationships related to this goal. 
Based on our data, certain observations were made that might indicate usefulness 
of FLA levels (IBD-SCAN™) in predicting clinical course and ultimately discharge 
disposition of hospitalized patients.  In comparing the two patient populations (medically 
responsive vs. those requiring rescue therapy), it was found that the median FLA values 
measured on the day of admission were quite different despite having similar ranges of 
values (steroid outcome = 653.3 g/mL; rescue outcome = 96.5 g/mL) but trended 
towards being quite similar upon day 3 of hospitalization (steroid outcome = 310.0 
g/mL; rescue outcome = 321.7 g/mL).  The differences in values, however, were not 
found to be statistically significant (p = 0.51).  
Interestingly, the change in FLA levels recorded on the day of admission and on 
hospital day 3 appeared to be different between the two populations.  Our data indicated 
that patients discharged on steroids (n=3) showed a negative percent change (-64.4%) in 
FLA levels during the first three days of their hospitalization, while patients that required 
rescue therapy (n=7) by the time of discharge demonstrated an increase in their FLA 
levels (+204.8%).  While the differences in mean values did not reach statistical 
significance (p = 0.18), this was a promising result: patients hospitalized for active 
disease and displaying decreasing FLA levels by hospital day 3 were more likely to be 
discharged on steroids, while those who showed stagnant or up-trending FLA levels were 
more likely to require more aggressive rescue therapy, such as tacrolimus or Infliximab.     
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The most important aspect of these findings is that it provides support for 
identifying and creating a specific objective measure for disease activity.  Physicians 
currently rely on numerous metrics, both subjective (e.g. PUCAI) and objective (e.g. 
endoscopy and serological inflammatory markers), but still encounter complications. 
While PUCAI has been accepted as a very effective evaluation of disease activity, minor 
changes in a patient's symptom report can have a drastic impact on their score, possibly 
triggering inappropriate changes in their care (Turner, et al. 2007).  Similarly, serologic 
inflammatory markers (CRP or ESR) may be confounded by other systemic ailments, 
making their use in treatment or prognostic algorithms less reliable.  Having the ability to 
use biomarkers specific to intestinal inflammation could provide doctors with more 
concrete and objective evidence on which to base their clinical impression and changes in 
therapy. Our data might substantiate this claim since longitudinal sample collection was 
executed.  This study design enabled the use of each patient as his/her own control in 
regards to FLA levels.  Rather than relying on absolute FLA measurement, the ranges of 
which may differ from patient to patient, physicians can instead measure the change in 
FLA for individual patients.  This personalized approach is likely to optimize medical 
decision-making and streamline not only clinical care but also expedite future 
intervention trials. 
 
Future Directions 
 Based on these encouraging preliminary findings, the Center for Inflammatory 
Bowel Diseases at Boston Children’s Hospital will look to expand the sample size.  
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While such efforts were made shortly after study initiation by increasing the age range for 
inclusion criteria (initially: 18, now: 21), recruiting more patients and obtaining daily 
samples for 3 or more days will be of utmost importance.  Related to sample collection, 
we will also attempt to collect samples and biochemical data over a greater length of 
time, in hopes that data collected on admission may provide more prognostic information 
in relation to patient disposition at discharge. 
 In regards to developing a more objective measure for prediction of discharge 
outcome, the potential for creating a composite measure of disease activity could prove 
extremely useful in substantiating medical treatment decisions.  Such composite scores 
could involve the incorporation of serologic measures (e.g. ESR, CRP, Albumin) with 
measured FLA levels.  By including these systemic markers with the colon-specific 
marker, disease activity and therapy outcome could be bolstered, mainly due to the 
presence of other objective measures of disease activity.  Another measure to possibly 
incorporate with FLA levels could be PUCAI scores. However, such measures are 
subjective and the validity may be limited by patient report and developmental stage.   
 The findings of this thesis and this research overall have positive implications for 
management of patient care with respect to IBD, specifically UC.  Studies of a larger 
scale that choose to analyze the predictive utility of FLA levels with respect to disease 
course and therapy outcome could prove to be quite valuable for both short-term and 
long-term treatment of patients with IBD. 
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